Clinical trial
Immunotherapy of HLA-A2 Positive Stage III/IV Melanoma Patients
NCT00112229 · Centre Hospitalier Universitaire Vaudois, Other · Completed
Key facts
| NCT number | NCT00112229 |
|---|---|
| Title | Immunotherapy of HLA-A2 Positive Stage III/IV Melanoma Patients |
| Official title | Immunotherapy of HLA-A2 Positive Stage III/IV Melanoma Patients With CpG7909, Tumor Antigenic Peptides and Montanide |
| Lead sponsor | Centre Hospitalier Universitaire Vaudois, Other |
| Collaborators | Ludwig Institute for Cancer Research |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Melanoma |
| Intervention type | Biological |
| Interventions | group 1, group 2, group 3, group 4 |
| Enrollment | 29 |
| Start date | Apr 1, 2003 |
| Primary completion | Aug 1, 2011 |
| Completion | Jun 1, 2012 |
| First posted | Jun 1, 2005 |
| Last update posted | Apr 22, 2013 |
| Countries | Switzerland |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: